December 11, 2025 | Pharmaphorum
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.
In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.
Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.
This content was provided by Inizio
Latest Content from Inizio
Conducting research in one of the world’s largest pharma markets
The process of demand calibration of preference share (down-weighting) is often a proprietary “black box” technique, which can mean that the client is unsure how the calibrated figure has been…
Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?
Published in eye for pharma 30 January by Marc Yates
Published in eye for pharma 12 December by Marc Yates
Published in Eye for Pharma 10 November by Marc Yates
Pegasus, the UK’s leading independent health communications consultancy, picked up the “Specialist Consultancy of the Year” award at the PRCA Awards 2014.
Brighton-based Pegasus, the UK’s leading independent health communications consultancy, is pleased to be supporting Naomi’s Flight – a bold and unique theatrical performance tour that highlights the impact of dementia…
Pegasus scoops the much-coveted “Consultancy of the Year” prize at the PR Week Awards 2014
In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in…
